Popular on TelAve


Similar on TelAve

Elabscience® Announces Antibody Technology Upgrade and Product Portfolio Enhancement

TelAve News/10880890
HOUSTON - TelAve -- Elabscience®, a leading global biotechnology company dedicated to providing high-quality reagents and services for life science research, today announced a major technological upgrade to its antibody product line. The initiative introduces recombinant rabbit monoclonal antibody technology, representing a significant step forward in antibody innovation, production efficiency, and performance consistency.

This upgrade reflects Elabscience's continued commitment to scientific excellence and innovation, in response to the growing global demand for high-performance and highly reproducible antibody reagents.

Driving Innovation with Recombinant Antibody Technology

With the rapid advancement of recombinant antibody engineering, Elabscience has fully integrated recombinant rabbit monoclonal antibody technology into its R&D and manufacturing processes. This new platform offers outstanding specificity, batch-to-batch consistency, stability, and scalability, addressing long-standing challenges associated with traditional hybridoma-derived antibodies.

"At Elabscience, we continuously strive to improve the scientific reliability of antibody-based research," said Dr. Lan, Director of Antibody Research and Development at Elabscience®. "By introducing recombinant rabbit monoclonal antibodies, we're empowering researchers with higher-quality, more consistent, and more efficient tools to accelerate discovery in fields such as immunology, oncology, and neuroscience."

More on TelAve News
Highlights of the Technology Upgrade

1. Advanced Molecular Design

● Utilizes humanized frameworks with rabbit variable region recombination, reducing heterologous immunogenicity, ideal for long-term in vivo studies.
● Combines phage display library screening with epitope prediction algorithms, enabling the generation of high-affinity antibodies (KD < 10⁻⁹ M) against complex conformational antigens such as GPCRs and ion channels.

2. Enhanced Production Process
● Employs CHO-S suspension cell culture in serum-free media, achieving batch yields over 500 mg, a 20-fold efficiency improvement compared with traditional hybridoma methods.
● Utilizes continuous flow chromatography purification, ensuring endotoxin levels below 0.1 EU/mg and meeting rigorous standards for preclinical research.

3. Stringent Quality Control
● Performs accelerated stability testing (activity retention > 90% after 14 days at 37°C).
● All batches undergo LC-MS peptide mapping and SEC-HPLC purity testing, with monomer content ≥ 98%.

Performance Comparison

Product Type: Anti-β-actin Antibody
Rabbit Polyclonal (Old): Inter-batch CV 12-15%

More on TelAve News
Recombinant Rabbit Monoclonal (New): Inter-batch CV < 3%

Product Type: Anti-PD-1 Antibody
Rabbit Polyclonal (Old): WB detection requires 1:500 dilution
Recombinant Rabbit Monoclonal (New): WB detection possible at up to 1:5000 dilution

Product Type: Anti-GFAP Antibody
Rabbit Polyclonal (Old): Supports IHC application only
Recombinant Rabbit Monoclonal (New): Compatible with IHC/ICC/IF multiple scenarios

These advancements deliver greater sensitivity, reproducibility, and versatility across research applications.

Contact

Elabscience Biotechnology Inc.

🌐 https://www.elabscience.com
📧 orders@elabscience.com

About Elabscience®
Elabscience® develops and produces high-quality reagents, including ELISA kits, antibodies, recombinant proteins, and assay kits to support global research in immunology, oncology, metabolism, and neuroscience.

Contact
Elabscience
***@elabscience.com


Source: Elabscience

Show All News | Report Violation

0 Comments

Latest on TelAve News